Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1432Pancreatic Neoplasms 860Carcinoma, Hepatocellular 743Stomach Neoplasms 647Colonic Neoplasms 447Rectal Neoplasms 404Esophageal Neoplasms 398Breast Neoplasms 331Carcinoma, Non-Small-Cell Lung 326Neoplasms 307Liver Neoplasms 282Cholangiocarcinoma 244Ovarian Neoplasms 243Lung Neoplasms 237Neoplasm Metastasis 235Gastrointestinal Neoplasms 217Melanoma 185Prostatic Neoplasms 166Esophageal Squamous Cell Carcinoma 166Biliary Tract Neoplasms 161Endometrial Neoplasms 143Uterine Cervical Neoplasms 130Squamous Cell Carcinoma of Head and Neck 129Carcinoma, Renal Cell 114Head and Neck Neoplasms 113Sarcoma 100Urinary Bladder Neoplasms 97Adenocarcinoma Of Esophagus 90Triple Negative Breast Neoplasms 86Anus Neoplasms 83

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Gastric Adenocarcinoma × Gastrointestinal × 1 year × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡